Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03591068 · ClinicalTrials.gov registry record · Phase 3
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
A Phase 3 study of Nasal Polyposis, sponsored by Optinose US.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
- 2
- Study locations
NCT03591068 is a Phase 3 study of Nasal Polyposis that has completed, run by Optinose US. The registered enrollment target is 11 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03591068, a Phase 3 study of Nasal Polyposis, has completed, sponsored by Optinose US.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video. The total planned number of subjects is approximately 10, with each subject receiving OPN-375 186 μg twice a day.
Conditions Studied
Interventions
- DRUG Fluticasone Propionate
Study Locations (2)
Colorado
- University of Colorado SOM, Department of Otolaryngology - Aurora
Texas
- University of Texas Health Science Center at Houston, McGovern Medical School, Dept. of Otolaryngology, Head and Neck Surgery - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2019-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03591068
The ClinicalTrials.gov registry entry for NCT03591068 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Optinose US, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nasal Polyposis appearing as the primary indexed condition, and to 1 intervention - of which Fluticasone Propionate is the first listed.
NCT03591068 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Texas.
Frequently Asked Questions
What is clinical trial NCT03591068 about?
NCT03591068 is a clinical study titled "Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video". This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video. The total planned number of subjects is approximately 10, with each subject receiving OPN-375 186 μg twice a day.
What is the current status of trial NCT03591068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2018-06-07. Estimated completion is 2019-02-22.
What conditions does trial NCT03591068 study?
This clinical trial studies the following conditions: Nasal Polyposis.
What interventions are being tested in trial NCT03591068?
The interventions under investigation include: Fluticasone Propionate (DRUG).
Who is sponsoring clinical trial NCT03591068?
This trial is sponsored by Optinose US, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03591068 being conducted?
This trial has 2 study locations across Colorado, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.